Sign in Subscribe
Drugs

Ceftobiprole Outperforms Vancomycin against MRSA, VISA, and VRSA in in Vitro Model

Strategic Insights

— 1 min read

A recent study from the University of Manitoba's Department of Medical Microbiology in Winnipeg, Canada, has demonstrated the superior pharmacodynamic activity of ceftobiprole compared to vancomycin against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA), and vancomycin-resistant Staphylococcus aureus (VRSA) in an in vitro model. The study, published in the Journal of Antimicrobial Chemotherapy, found that ceftobiprole achieved 100% bactericidal activity against all tested strains, whereas vancomycin demonstrated limited or no activity against VRSA.

Key Takeaways:

  • Ceftobiprole achieved 100% bactericidal activity against MSSA, CA-MRSA, HA-MRSA, VISA, and VRSA at 16 and 24 h in the in vitro model.
  • Vancomycin fAUC(24)/MIC of 340 resulted in a 1.8-2.6 log(10) reduction in colony count at 24 h against MSSA and MRSA with a vancomycin MIC of 1 mg/L.
  • Vancomycin fAUC(24)/MIC of 85-170 resulted in a 0.4-0.7 log(10) reduction at 24 h against VISA with a vancomycin MIC of 2-4 mg/L.
  • Vancomycin demonstrated limited effect against VRSA with a vancomycin MIC of 64 mg/L.
  • Ceftobiprole's pharmacodynamic activity was superior to vancomycin against all tested strains, indicating its potential as a treatment option for infections caused by MRSA, VISA, and VRSA.
  • Ghada G. Zhanel and colleagues from the University of Manitoba's Department of Medical Microbiology conducted the study, which was published in the Journal of Antimicrobial Chemotherapy.

Statistics:

  • Ceftobiprole T MIC of ≥100% (ceftobiprole MICs, ≥3 log(10) killing) against MSSA, CA-MRSA, HA-MRSA, VISA, and VRSA at 16 and 24 h.
  • Vancomycin fAUC(24)/MIC of 340 resulted in a 1.8-2.6 log(10) reduction in colony count at 24 h against MSSA and MRSA with a vancomycin MIC of 1 mg/L.
  • Vancomycin fAUC(24)/MIC of 85-170 resulted in a 0.4-0.7 log(10) reduction at 24 h against VISA with a vancomycin MIC of 2-4 mg/L.

Sources:

  • Zhanel, G. G., et al. "Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model." Journal of Antimicrobial Chemotherapy 64.2 (2009): 364-369.

Read more